Actionable news
All posts from Actionable news
Actionable news in OMER: Omeros Corporation,

Omeros Corporation just filed a prospectus, suggesting it plans to soon issue some securities

Omeros Corporation just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:

Unless otherwise indicated in the prospectus supplement, we intend to use the net proceeds from the sale of securities offered under this prospectus for general corporate purposes including expenses related to the continued commercialization of OMIDRIA, research and development expenses such as funding clinical trials, pre-clinical studies, manufacturing development and costs associated with otherwise advancing our drug candidates toward Ne w Drug Application and Biologic License Application submissions. We may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to our own, and other capital expenditures. We will set forth in the prospectus supplement our intended use for the net proceeds received from the sale of any securities. Pending the use of such proceeds, we intend to invest the net proceeds in short-term, investment grade, interest-bearing instruments.


The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Omeros Corporation makes a similar move, sign up!

Other recent filings from the company include the following:

Omeros Corporation just filed a prospectus, suggesting it plans to soon issue some securities - April 22, 2016
Omeros Corporation releases salary data. CEO sees compensation fall -82% - April 22, 2016
Omeros Corporation's VP Patent and General Counsel just cashed-in 15,900 options - April 15, 2016